ClinicalTrials.gg
CompletedNCT05901714Updated Aug 7, 2024

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

A Phase 1 interventional study of Afimetoran and Phenytoin in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-07.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will consist of 2 parts. The study will evaluate whether administration of phenytoin impacts the single-dose drug levels of afimetoran and BMT-271199 (Part 1) and will evaluate whether multiple administrations of afimetoran impact the drug levels of midazolam and 1-hydroxymidazolam (Part 2).

02

Conditions studied

  • Healthy Participants

Keywords

  • BMS-986256
  • Afimetoran
  • Midazolam
  • CYP3A4
  • Phenytoin
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 19.0 kilograms per meter squared (kg/m\^2) to 32.0 kg/m2, inclusive, and body weight ≥ 55 kg, at screening.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness or any other condition listed as a in the phenytoin (Part 1) or midazolam (Part 2) package inserts.
  • History of seizure (including simple febrile seizure), epilepsy, severe head injury (including concussion), multiple sclerosis, or other known neurological condition which the investigator considers to be .
  • Current or recent (within 3 months of study intervention administration) GI disease that could impact upon the absorption of study intervention.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Part 1: Afimetoran followed by phenytoin + afimetoran

    Drug: Afimetoran · Drug: Phenytoin

  • Experimental
    Part 2: Midazolam followed by afimetoran + midazolam

    Drug: Afimetoran · Drug: Midazolam

Interventions

  • Specified dose on specified days

    Also known as: BMS-986256

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Parts 1 and 2

    Time frame: Up to 53 days

  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])

    Parts 1 and 2

    Time frame: Up to 53 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])

    Parts 1 and 2

    Time frame: Up to 53 days

Secondary outcomes

  1. Time to attain maximum observed plasma concentration (Tmax)

    Parts 1 and 2

    Time frame: Up to 53 days

  2. Terminal half-life (T-Half)

    Parts 1 and 2

    Time frame: Up to 53 days

  3. Apparent total body clearance of the drug from the plasma (CLT/F)

    Parts 1 and 2

    Time frame: Up to 53 days

  4. Number of participants with adverse events (AEs)

    Parts 1 and 2

    Time frame: Up to 124 days

  5. Number of participants with clinical laboratory abnormalities

    Parts 1 and 2

    Time frame: Up to 66 days

  6. Number of participants with physical examination abnormalities

    Parts 1 and 2

    Time frame: Up to 66 days

  7. Number of participants with vital sign abnormalities

    Parts 1 and 2

    Time frame: Up to 66 days

  8. Number of participants with electrocardiogram (ECG) abnormalities

    Parts 1 and 2

    Time frame: Up to 66 days

07

Study locations

1 site
  • Local Institution - 0001
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Apr 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 13, 2023
StartActual
Jun 14, 2023
Primary completionActual
Apr 11, 2024
CompletionActual
Apr 11, 2024
Last update
Aug 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05901714
Responsible party
Sponsor
First posted
Jun 13, 2023
Start date
Jun 14, 2023
Primary completion
Apr 11, 2024
Completion
Apr 11, 2024
Last update
Aug 7, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimetoran

Start the discussion